sumatriptan has been researched along with Common Migraine in 36 studies
Sumatriptan: A serotonin agonist that acts selectively at 5HT1 receptors. It is used in the treatment of MIGRAINE DISORDERS.
sumatriptan : A sulfonamide that consists of N,N-dimethyltryptamine bearing an additional (N-methylsulfamoyl)methyl substituent at position 5. Selective agonist for a vascular 5-HT1 receptor subtype (probably a member of the 5-HT1D family). Used (in the form of its succinate salt) for the acute treatment of migraine with or without aura in adults.
| Excerpt | Relevance | Reference |
|---|---|---|
| " This study aims to evaluate the efficacy of ginger in the ablation of common migraine attack in comparison to sumatriptan therapy." | 9.19 | Comparison between the efficacy of ginger and sumatriptan in the ablative treatment of the common migraine. ( Golipour, F; Maghbooli, M; Moghimi Esfandabadi, A; Yousefi, M, 2014) |
| " This study was conducted to evaluate the efficacy and tolerability of sumatriptan/naproxen sodium for the acute treatment of probable migraine without aura." | 9.19 | Sumatriptan/naproxen sodium for the acute treatment of probable migraine without aura: a randomized study. ( Aurora, S; Derosier, F; Goldstein, J; Lener, SE; Lipton, RB; McDonald, SA; Runken, MC; Saiers, J; Silberstein, S; White, J, 2014) |
| " We randomized patients to either naproxen 500 mg or sumatriptan 100 mg for headache recurrence after ED discharge." | 9.14 | Treating headache recurrence after emergency department discharge: a randomized controlled trial of naproxen versus sumatriptan. ( Bijur, PE; Dua, N; Esses, D; Friedman, BW; Gallagher, EJ; Heins, A; Hochberg, M; Lipton, RB; Sasso, P; Solorzano, C; Xia, S, 2010) |
| "To study the efficacy and practicality of treating headache in professional footballers with intranasal sumatriptan." | 7.73 | Open label study of intranasal sumatriptan (Imigran) for footballer's headache. ( Heywood, J; McCrory, P; Ugoni, A, 2005) |
| " This study aims to evaluate the efficacy of ginger in the ablation of common migraine attack in comparison to sumatriptan therapy." | 5.19 | Comparison between the efficacy of ginger and sumatriptan in the ablative treatment of the common migraine. ( Golipour, F; Maghbooli, M; Moghimi Esfandabadi, A; Yousefi, M, 2014) |
| " This study was conducted to evaluate the efficacy and tolerability of sumatriptan/naproxen sodium for the acute treatment of probable migraine without aura." | 5.19 | Sumatriptan/naproxen sodium for the acute treatment of probable migraine without aura: a randomized study. ( Aurora, S; Derosier, F; Goldstein, J; Lener, SE; Lipton, RB; McDonald, SA; Runken, MC; Saiers, J; Silberstein, S; White, J, 2014) |
| "Patients presenting with moderate to severe intensity migraine without aura were randomized to receive either 400 mg of iVPA or 10 mg intramuscular metoclopramide + 6 mg SQ sumatriptan (30 patients in each study arm)." | 5.17 | A randomized open-label study of sodium valproate vs sumatriptan and metoclopramide for prolonged migraine headache. ( Bakhshayesh, B; Hatamian, H; Hossieninezhad, M; Rezania, K; Seyed Saadat, SM, 2013) |
| " We randomized patients to either naproxen 500 mg or sumatriptan 100 mg for headache recurrence after ED discharge." | 5.14 | Treating headache recurrence after emergency department discharge: a randomized controlled trial of naproxen versus sumatriptan. ( Bijur, PE; Dua, N; Esses, D; Friedman, BW; Gallagher, EJ; Heins, A; Hochberg, M; Lipton, RB; Sasso, P; Solorzano, C; Xia, S, 2010) |
| " From November 2001 to March 2002, patients meeting International Headache Society criteria for migraine (with > or =2 of the following: unilateral location, pulsating quality, moderate or severe intensity, aggravation by moderate physical activity; and > or =1 of: phonophobia and phonophobia, nausea and/or vomiting) and with no evidence of bacterial rhinosinusitis were enrolled and randomized in a 1:1 ratio via computer-generated randomization schedule to receive either 1 sumatriptan 50-mg tablet or matching placebo tablet." | 5.12 | Efficacy of sumatriptan tablets in migraineurs self-described or physician-diagnosed as having sinus headache: a randomized, double-blind, placebo-controlled study. ( Ames, M; Blumenthal, H; Ishkanian, G; Richardson, MS; Webster, CJ, 2007) |
| "To study the efficacy and practicality of treating headache in professional footballers with intranasal sumatriptan." | 3.73 | Open label study of intranasal sumatriptan (Imigran) for footballer's headache. ( Heywood, J; McCrory, P; Ugoni, A, 2005) |
| "A total of 37 patients with migraine without aura were enrolled between July 2018 to December 2019." | 3.01 | Early treatment with sumatriptan prevents PACAP38-induced migraine: A randomised clinical trial. ( Al-Karagholi, MA; Ashina, M; Christensen, CE; Coskun, H; Egeberg, A; Ghanizada, H; Hannibal, J; Thyssen, JP; Wienholtz, NKF; Zhang, DG, 2021) |
| "The slow rate and low extent of absorption of the drug during the first 2 h after dosing observed in patients of group B could explain their unsatisfactory response to oral sumatriptan." | 2.73 | Interindividual variability of oral sumatriptan pharmacokinetics and of clinical response in migraine patients. ( Bertolini, A; Coccia, C; Ferrari, A; Pinetti, D; Sternieri, E, 2008) |
| "Sumatriptan nasal spray was administered 120 min after the onset of the attack." | 2.71 | Sumatriptan causes parallel decrease in plasma calcitonin gene-related peptide (CGRP) concentration and migraine headache during nitroglycerin induced migraine attack. ( Bagdy, G; Jakab, B; Juhasz, G; Nemeth, J; Szolcsanyi, J; Zsombok, T, 2005) |
| "Almotriptan malate is a novel, selective serotonin(1B/D) agonist, or triptan, developed for the abortive treatment of migraine." | 2.70 | Oral almotriptan vs. oral sumatriptan in the abortive treatment of migraine: a double-blind, randomized, parallel-group, optimum-dose comparison. ( Gomez-Mancilla, B; Grosz, DE; Jirgens, KJ; Rowland, CR; Spierings, EL; Whaley, FS, 2001) |
| "The management of pediatric migraine requires a balance of biobehavioral measures coupled with agents for acute treatment and, if needed, daily preventive medicines." | 2.43 | The treatment of pediatric migraine. ( Lewis, DW; Sowell, M; Winner, P; Yonker, M, 2005) |
| "A similar pattern was observed for migraine-free results 2 hours postdose (50 mg, 42%; 100 mg, 47%; placebo, 20%; P < 0." | 2.43 | Early intervention in migraine with sumatriptan tablets 50 mg versus 100 mg: a pooled analysis of data from six clinical trials. ( Ames, M; Landy, S; Richardson, M; Winner, P, 2005) |
| "The so-called menstrual migraine, which occurs immediately before, during or at the end of the menstrual flow, has been a largely undefined condition, including some clinical subtypes which are not well defined." | 2.42 | Update on menstrual migraine: from clinical aspects to therapeutical strategies. ( Allais, G; Benedetto, C, 2004) |
| "Treatment with sumatriptan during migraine attacks appeared to be associated with a decrease in 5-HT1B receptor binding, a finding that is most likely associated with the binding of sumatriptan to central 5-HT1B receptors, but the contribution of ongoing cerebral serotonin release to the lower binding cannot be excluded; the migraine attack-associated decrease in binding could indicate that migraine attacks are associated with increases in endogenous serotonin." | 1.51 | Association Between Sumatriptan Treatment During a Migraine Attack and Central 5-HT1B Receptor Binding. ( Ashina, M; Deen, M; Dyssegaard, A; Hansen, HD; Hougaard, A; Knudsen, GM; Schain, M, 2019) |
| "41." | 1.46 | Clinical characteristics and overuse patterns of medication overuse headache: Retrospective case-series study. ( Kluonaitis, K; Petrauskiene, E; Ryliskiene, K, 2017) |
| "Photophobia is an abnormal sensitivity to light experienced by migraineurs during attacks." | 1.37 | A PET study of photophobia during spontaneous migraine attacks. ( Boulloche, N; Denuelle, M; Fabre, N; Géraud, G; Payoux, P; Trotter, Y, 2011) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 1 (2.78) | 18.2507 |
| 2000's | 17 (47.22) | 29.6817 |
| 2010's | 17 (47.22) | 24.3611 |
| 2020's | 1 (2.78) | 2.80 |
| Authors | Studies |
|---|---|
| Wienholtz, NKF | 1 |
| Christensen, CE | 1 |
| Zhang, DG | 1 |
| Coskun, H | 1 |
| Ghanizada, H | 1 |
| Al-Karagholi, MA | 1 |
| Hannibal, J | 1 |
| Egeberg, A | 1 |
| Thyssen, JP | 1 |
| Ashina, M | 3 |
| Kluonaitis, K | 1 |
| Petrauskiene, E | 1 |
| Ryliskiene, K | 1 |
| Deen, M | 1 |
| Hougaard, A | 1 |
| Hansen, HD | 1 |
| Schain, M | 1 |
| Dyssegaard, A | 1 |
| Knudsen, GM | 1 |
| Maghbooli, M | 1 |
| Golipour, F | 1 |
| Moghimi Esfandabadi, A | 1 |
| Yousefi, M | 1 |
| Silberstein, S | 1 |
| McDonald, SA | 1 |
| Goldstein, J | 2 |
| Aurora, S | 1 |
| Lener, SE | 1 |
| White, J | 1 |
| Runken, MC | 2 |
| Saiers, J | 1 |
| Derosier, F | 1 |
| Lipton, RB | 2 |
| Ward, TN | 1 |
| Hansen, JM | 1 |
| Goadsby, PJ | 1 |
| Charles, A | 1 |
| Ducros, A | 1 |
| Lampl, C | 1 |
| Huber, G | 1 |
| Haas, S | 1 |
| Rittberger, E | 1 |
| Diener, HC | 1 |
| Nagata, E | 1 |
| Moriguchi, H | 1 |
| Takizawa, S | 1 |
| Horie, T | 1 |
| Yanagimachi, N | 1 |
| Takagi, S | 1 |
| Friedman, BW | 1 |
| Solorzano, C | 1 |
| Esses, D | 1 |
| Xia, S | 1 |
| Hochberg, M | 1 |
| Dua, N | 1 |
| Heins, A | 1 |
| Sasso, P | 1 |
| Bijur, PE | 1 |
| Gallagher, EJ | 1 |
| Facchinetti, F | 1 |
| Allais, G | 2 |
| Nappi, RE | 1 |
| Gabellari, IC | 1 |
| Di Renzo, GC | 1 |
| Genazzani, AR | 1 |
| Bellafronte, M | 1 |
| Roncolato, M | 1 |
| Benedetto, C | 2 |
| Watanabe, Y | 1 |
| Tanaka, H | 1 |
| Dan, I | 1 |
| Sakurai, K | 1 |
| Kimoto, K | 1 |
| Takashima, R | 1 |
| Hirata, K | 1 |
| Brennan, KC | 1 |
| Denuelle, M | 1 |
| Boulloche, N | 1 |
| Payoux, P | 1 |
| Fabre, N | 1 |
| Trotter, Y | 1 |
| Géraud, G | 1 |
| Rothrock, JF | 1 |
| Asghar, MS | 1 |
| Hansen, AE | 1 |
| Amin, FM | 1 |
| van der Geest, RJ | 1 |
| Koning, Pv | 1 |
| Larsson, HB | 1 |
| Olesen, J | 1 |
| Levy, D | 1 |
| Burstein, R | 1 |
| Cady, R | 2 |
| Banks, J | 1 |
| Nett, RB | 1 |
| Bennett, N | 1 |
| Turner, IM | 1 |
| Ruoff, GE | 1 |
| Landy, SH | 1 |
| Farmer, K | 1 |
| Juhász, M | 1 |
| Tarrasch, J | 1 |
| Shevel, E | 1 |
| Bakhshayesh, B | 1 |
| Seyed Saadat, SM | 1 |
| Rezania, K | 1 |
| Hatamian, H | 1 |
| Hossieninezhad, M | 1 |
| Weidmann, E | 1 |
| Unger, J | 1 |
| Blair, S | 1 |
| Friesen, C | 1 |
| Hart, C | 1 |
| D'Andrea, G | 1 |
| Terrazzino, S | 1 |
| Leon, A | 1 |
| Fortin, D | 1 |
| Perini, F | 1 |
| Granella, F | 1 |
| Bussone, G | 1 |
| Juhasz, G | 1 |
| Zsombok, T | 1 |
| Jakab, B | 1 |
| Nemeth, J | 1 |
| Szolcsanyi, J | 1 |
| Bagdy, G | 1 |
| Peters, EW | 1 |
| de Bruijn, SF | 1 |
| Lewis, DW | 1 |
| Yonker, M | 1 |
| Winner, P | 2 |
| Sowell, M | 1 |
| McCrory, P | 1 |
| Heywood, J | 1 |
| Ugoni, A | 1 |
| Landy, S | 1 |
| Richardson, M | 1 |
| Ames, M | 2 |
| Vanmolkot, F | 1 |
| Van der Schueren, B | 1 |
| de Hoon, J | 1 |
| Ishkanian, G | 1 |
| Blumenthal, H | 1 |
| Webster, CJ | 1 |
| Richardson, MS | 1 |
| Ferrari, A | 1 |
| Pinetti, D | 1 |
| Bertolini, A | 1 |
| Coccia, C | 1 |
| Sternieri, E | 1 |
| Dahlöf, C | 1 |
| Boska, MD | 1 |
| Welch, KM | 1 |
| Schultz, L | 1 |
| Nelson, J | 1 |
| Mulder, EJ | 1 |
| Linssen, WH | 1 |
| Passchier, J | 1 |
| de Geus, EJ | 1 |
| Spierings, EL | 1 |
| Gomez-Mancilla, B | 1 |
| Grosz, DE | 1 |
| Rowland, CR | 1 |
| Whaley, FS | 1 |
| Jirgens, KJ | 1 |
| Trial | Phase | Enrollment | Study Type | Start Date | Status | ||
|---|---|---|---|---|---|---|---|
| Investigation of PACAP38 Induced Headache, Migraine and Flushing in Patients With Migraine[NCT03881644] | 37 participants (Actual) | Interventional | 2018-07-17 | Completed | |||
| Understanding the Role of the External Carotid Artery in the Pathophysiology of Migraine Pain[NCT03026101] | 20 participants (Anticipated) | Interventional | 2017-01-31 | Enrolling by invitation | |||
| "An Open-label Study to Evaluate Completeness of Response Following Treatment With Treximet™ for Migraine"[NCT00893737] | Phase 4 | 147 participants (Actual) | Interventional | 2009-06-30 | Completed | ||
| [information is prepared from clinicaltrials.gov, extracted Sep-2024] | |||||||
"CORS scores for Pain (0-4), Associated Symptoms (0-4), Limbic/Affective Symptoms (0-5), and Speed of Return to Functionality (1-5), represent outcome measures that are relevant to patients. Higher scores represent better treatment efficacy.~The analysis compares CORS scores for usual triptan (pre-study) versus (vs.) Treximet (study medication)." (NCT00893737)
Timeframe: Visit 1 (screening) and Visit 2 (study completion following 2-month treatment period)
| Intervention | Units on a scale (Mean) | |||
|---|---|---|---|---|
| Pain Score | Associated Symptoms Score | Limbic Symptoms Score | Functionality Score | |
| Treximet | 0.17 | 0.07 | 0.03 | 0.10 |
Scores calculated for (1) Efficacy (2) Functionality (3) Ease of use (4) Cost. Higher score represents better treatment satisfaction. (NCT00893737)
Timeframe: Visit 1 (screening) and Visit 2 (study completion following 2-month treatment period)
| Intervention | Units on a scale (Mean) | |||
|---|---|---|---|---|
| Efficacy | Functionality | Ease of Use | Cost | |
| Treximet | 8.61 | 13.86 | 2.76 | 7.28 |
CORS completed at Visit 1 regarding participant pre-study triptan and at Visit 2 regarding Treximet taken in study. Areas of therapeutic advantage evaluated: How often does 1 dose completely relieve (1) headache pain (2) neck/shoulder pain (3) nausea (4) light sensitivity (5) sound sensitivity (6) irritability. How quickly can/do you (1) concentrate or think clearly (2) resume normal activities (3) function normally (4) feel completely normal. How confident are you that (1) one dose will completely relieve migraine within 2 hours (2) once relieved, migraine will not return within 24 hours. (NCT00893737)
Timeframe: Visit 1 (screening) and Visit 2 (study completion following 2-month treatment period)
| Intervention | Percent of Participants (Number) | |||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| How often 1 dose relieves headache pain | How often 1 dose relieves neck/shoulder pain | How often 1 dose relieves nausea | How often 1 dose relieves light sensitivity | How often 1 dose relieves sound sensitivity | How often 1 dose relieves irritability | How quickly can you concentrate or think clearly | How quickly can you resume normal activities | How quickly can you function normally | How quickly do you feel completely normal | Confidence 1 dose will relieve migraine in 2 hours | Confidence migraine will not return in 24 hours | |
| Treximet | 42 | 52 | 43 | 42 | 45 | 36 | 31 | 32 | 32 | 36 | 33 | 38 |
3 reviews available for sumatriptan and Common Migraine
| Article | Year |
|---|---|
Update on menstrual migraine: from clinical aspects to therapeutical strategies.
Topics: Female; Humans; Menstruation; Migraine Disorders; Migraine without Aura; Serotonin Receptor Agonists | 2004 |
The treatment of pediatric migraine.
Topics: Adrenergic beta-Antagonists; Anticonvulsants; Antidepressive Agents; Antiemetics; Biofeedback, Psych | 2005 |
Early intervention in migraine with sumatriptan tablets 50 mg versus 100 mg: a pooled analysis of data from six clinical trials.
Topics: Adult; Dose-Response Relationship, Drug; Double-Blind Method; Drug Administration Schedule; Female; | 2005 |
16 trials available for sumatriptan and Common Migraine
| Article | Year |
|---|---|
Early treatment with sumatriptan prevents PACAP38-induced migraine: A randomised clinical trial.
Topics: Adolescent; Adult; Cross-Over Studies; Double-Blind Method; Humans; Incidence; Middle Aged; Migraine | 2021 |
Comparison between the efficacy of ginger and sumatriptan in the ablative treatment of the common migraine.
Topics: Administration, Oral; Adult; Analgesics; Antiemetics; Double-Blind Method; Female; Humans; Male; Mig | 2014 |
Sumatriptan/naproxen sodium for the acute treatment of probable migraine without aura: a randomized study.
Topics: Adult; Analgesics; Double-Blind Method; Drug Combinations; Female; Humans; Male; Migraine without Au | 2014 |
Reduced efficacy of sumatriptan in migraine with aura vs without aura.
Topics: Adult; Databases, Factual; Dihydroergotamine; Double-Blind Method; Female; Humans; Male; Migraine wi | 2015 |
Difference in triptan effect in patients with migraine and early allodynia.
Topics: Administration, Intranasal; Administration, Oral; Adolescent; Adult; Face; Female; Humans; Male; Mid | 2008 |
Treating headache recurrence after emergency department discharge: a randomized controlled trial of naproxen versus sumatriptan.
Topics: Adult; Analgesics; Double-Blind Method; Emergency Service, Hospital; Female; Headache; Humans; Male; | 2010 |
Sumatriptan (50 mg tablets vs. 25 mg suppositories) in the acute treatment of menstrually related migraine and oral contraceptive-induced menstrual migraine: a pilot study.
Topics: Administration, Oral; Administration, Rectal; Adult; Contraceptives, Oral; Cross-Over Studies; Femal | 2010 |
Multi-center comparison of response to a single tablet of sumatriptan 85 mg and naproxen 500 mg vs usual therapy treating multiple migraine attacks as measured by the completeness of response survey.
Topics: Acute Disease; Adolescent; Adult; Aged; Anti-Inflammatory Agents, Non-Steroidal; Drug Therapy, Combi | 2011 |
A randomized open-label study of sodium valproate vs sumatriptan and metoclopramide for prolonged migraine headache.
Topics: Acute Disease; Adult; Analgesics; Dopamine Antagonists; Drug Therapy, Combination; Female; GABA Agen | 2013 |
An open-label study to assess changes in efficacy and satisfaction with migraine care when patients have access to multiple sumatriptan succinate formulations.
Topics: Administration, Intranasal; Administration, Oral; Adult; Female; Humans; Injections, Subcutaneous; M | 2003 |
Sumatriptan causes parallel decrease in plasma calcitonin gene-related peptide (CGRP) concentration and migraine headache during nitroglycerin induced migraine attack.
Topics: Biomarkers; Calcitonin Gene-Related Peptide; Female; Humans; Middle Aged; Migraine without Aura; Nit | 2005 |
Efficacy of sumatriptan tablets in migraineurs self-described or physician-diagnosed as having sinus headache: a randomized, double-blind, placebo-controlled study.
Topics: Administration, Oral; Adolescent; Adult; Aged; Dizziness; Double-Blind Method; Female; Humans; Male; | 2007 |
Interindividual variability of oral sumatriptan pharmacokinetics and of clinical response in migraine patients.
Topics: Administration, Oral; Area Under Curve; Chromatography, High Pressure Liquid; Female; Half-Life; Hum | 2008 |
How to assess patient preference of migraine treatments.
Topics: Adult; Analgesics; Cross-Over Studies; Female; Humans; Male; Middle Aged; Migraine Disorders; Migrai | 1999 |
Effects of the anti-migraine drug sumatriptan on muscle energy metabolism: relationship to side-effects.
Topics: Adenosine Triphosphate; Adult; Creatine Kinase; Energy Metabolism; Female; Humans; Magnetic Resonanc | 2000 |
Oral almotriptan vs. oral sumatriptan in the abortive treatment of migraine: a double-blind, randomized, parallel-group, optimum-dose comparison.
Topics: Administration, Oral; Adolescent; Adult; Aged; Cardiovascular System; Chi-Square Distribution; Doubl | 2001 |
17 other studies available for sumatriptan and Common Migraine
| Article | Year |
|---|---|
Clinical characteristics and overuse patterns of medication overuse headache: Retrospective case-series study.
Topics: Adult; Analgesics; Analgesics, Opioid; Female; Headache Disorders; Headache Disorders, Secondary; Hu | 2017 |
Association Between Sumatriptan Treatment During a Migraine Attack and Central 5-HT1B Receptor Binding.
Topics: Adult; Benzopyrans; Brain; Female; Humans; Male; Migraine without Aura; Morpholines; Piperazines; Po | 2019 |
Does the presence of aura inform us regarding migraine severity and response to treatment?
Topics: Dihydroergotamine; Female; Humans; Male; Migraine with Aura; Migraine without Aura; Sumatriptan; Vas | 2015 |
[National ranking exam. N64. What could fall at the exam?].
Topics: Adult; Anti-Inflammatory Agents, Non-Steroidal; Antiemetics; Benzoxepins; Female; Humans; Ketoprofen | 2008 |
The middle meningial artery during a migraine attack: 3T magnetic resonance angiography study.
Topics: Adult; Female; Humans; Injections, Subcutaneous; Magnetic Resonance Angiography; Meningeal Arteries; | 2009 |
Monitoring cortical hemodynamic changes after sumatriptan injection during migraine attack by near-infrared spectroscopy.
Topics: Adult; Case-Control Studies; Cerebral Cortex; Cerebrovascular Circulation; Female; Hemodynamics; Hum | 2011 |
Turn down the lights!: an irritable occipital cortex in migraine without aura.
Topics: Analgesics; Cerebrovascular Circulation; Humans; Migraine without Aura; Photophobia; Sumatriptan; Ti | 2011 |
A PET study of photophobia during spontaneous migraine attacks.
Topics: Adult; Analgesics; Analysis of Variance; Cerebrovascular Circulation; Female; Humans; Injections, Su | 2011 |
Membership survey: use of oral triptans and injectable sumatriptan within the same 24-hour period.
Topics: Drug Utilization; Health Care Surveys; Humans; Injections; Migraine without Aura; Societies, Medical | 2011 |
Evidence for a vascular factor in migraine.
Topics: Adult; Arteries; Female; Humans; Injections, Subcutaneous; Magnetic Resonance Angiography; Male; Men | 2011 |
The vascular theory of migraine: leave it or love it?
Topics: Arteries; Ergotamine; Humans; Magnetic Resonance Angiography; Middle Cerebral Artery; Migraine witho | 2011 |
Confirmation of the extracranial site of action of sumatriptan.
Topics: Arteries; Female; Humans; Magnetic Resonance Angiography; Male; Meninges; Migraine without Aura; Sum | 2011 |
Elevated levels of circulating trace amines in primary headaches.
Topics: Adolescent; Adult; Chromatography, High Pressure Liquid; Cluster Headache; Diet; Female; Headache; H | 2004 |
Migraine treated with acyclovir.
Topics: Acyclovir; Adult; Diagnosis, Differential; Encephalitis, Herpes Simplex; Female; Herpesvirus 1, Huma | 2005 |
Open label study of intranasal sumatriptan (Imigran) for footballer's headache.
Topics: Administration, Intranasal; Headache; Humans; Migraine Disorders; Migraine without Aura; Pain Measur | 2005 |
Sumatriptan causes parallel decrease in plasma CGRP concentration and migraine headache during nitroglycerin-induced migraine attack.
Topics: Biomarkers; Calcitonin Gene-Related Peptide; Female; Humans; Middle Aged; Migraine without Aura; Nit | 2006 |
Interictal and postictal contingent negative variation in migraine without aura.
Topics: Adult; Central Nervous System; Cerebral Cortex; Contingent Negative Variation; Female; Humans; Male; | 2001 |